Last updated: September 7, 2026
Plasma protein fraction (human) is a mature, niche plasma-derived biologic with limited public revenue disclosure, no meaningful remaining regulatory exclusivity, and substantial manufacturing barriers. In the United States, the principal marketed product is Plasmanate, a 5% human plasma protein solution manufactured by Grifols. Demand is concentrated in hospitals and emergency-care settings requiring plasma-volume replacement. Its commercial position is constrained by competition from human albumin, crystalloids and synthetic volume expanders, while supply remains dependent on plasma collection and fractionation capacity.
Plasma Protein Fraction (Human) Market Dynamics, Patent Status, and Financial Trajectory
What is plasma protein fraction (human)?
Plasma protein fraction (human), or PPF, is a sterile solution of human plasma proteins used to restore or maintain circulating blood volume. The principal product in the U.S. market is Plasmanate, a 5% solution manufactured by Grifols Therapeutics LLC.
PPF is produced from pooled human plasma. The protein mixture generally contains albumin and globulins, with albumin representing the largest component. It is administered intravenously and is used when plasma-volume replacement is clinically required, including hypovolemia associated with blood or plasma loss.
PPF differs from purified human serum albumin because it contains a broader mixture of plasma proteins. That difference affects clinical positioning, manufacturing, labeling and regulatory treatment.
| Attribute |
Plasma protein fraction (human) |
| Product type |
Plasma-derived biologic |
| Common U.S. product |
Plasmanate |
| Strength |
5% |
| Route |
Intravenous |
| Primary use |
Restoration or maintenance of circulating blood volume |
| Regulatory pathway |
Biologics license application |
| Principal manufacturer |
Grifols |
| U.S. product exclusivity |
Expired |
| Orange Book status |
Not listed as a conventional small-molecule drug |
| Main commercial substitutes |
Human albumin, crystalloids and other plasma-volume expanders |
Source: U.S. Food and Drug Administration, Plasmanate prescribing information.
What is the FDA regulatory status of plasma protein fraction?
Plasmanate is an FDA-licensed biologic product under Biologics License Application 018851. The FDA labeling identifies the product as plasma protein fraction, human, 5%, for intravenous use.
The product is regulated under the Public Health Service Act and the biologics provisions of the Federal Food, Drug, and Cosmetic Act. It is not treated like a conventional tablet or injectable small molecule approved under an abbreviated new drug application.
The principal regulatory issues are product quality, donor eligibility, viral safety, fractionation controls, sterility, stability and consistency between manufacturing lots. Because the active material is derived from pooled human plasma, the FDA evaluates the entire manufacturing system rather than only the final formulation.
PPF is not generally represented in the Orange Book in the same manner as an abbreviated new drug application product. The relevant regulatory record is the biologics license and associated product labeling. The FDA Purple Book is the more relevant reference for biological products, although mature plasma-derived products may not generate an active biosimilar market.
When does plasma protein fraction lose exclusivity?
Commercial exclusivity for the original PPF product has expired. PPF is an established plasma-derived product rather than a recently approved biologic with remaining reference-product exclusivity.
The absence of active regulatory exclusivity does not mean that market entry is easy. A competing manufacturer would still need to establish:
- A compliant source-plasma supply;
- Donor screening and testing systems;
- Validated fractionation and purification processes;
- Viral inactivation and removal controls;
- Lot-release testing;
- Manufacturing consistency;
- Clinical and comparability support appropriate to the FDA pathway.
For mature plasma-derived products, manufacturing capability is usually a more significant barrier than patent protection.
What patents protect plasma protein fraction (human)?
The core concept of PPF is old and is not protected by a commercially meaningful new chemical entity patent. Historical patents covering plasma fractionation, albumin-containing solutions and viral-inactivation methods have generally expired or become less important than process know-how and regulatory controls.
No active product-specific patent is identified in the Plasmanate FDA label as the source of current market exclusivity. The commercial protection surrounding the product is primarily operational:
- Access to qualified source plasma.
- Validated fractionation and viral-safety processes.
- Manufacturing capacity.
- FDA inspection history and quality systems.
- Hospital contracting and distribution relationships.
Are formulation patents important for PPF?
Formulation patents have limited strategic importance for a conventional 5% PPF solution. The product is a relatively established aqueous protein formulation rather than a differentiated delivery system.
Potential formulation claims could address stabilizers, protein concentration, containers, storage conditions or specific viral-inactivation conditions. Those claims would not necessarily block a competing manufacturer from producing an equivalent 5% plasma-protein product using a different process.
Are method-of-use patents relevant?
Method-of-use patent risk is limited. The principal use, restoration or maintenance of circulating blood volume, is an established clinical use. A later patent would need to claim a narrower patient population, administration protocol or combination treatment to create meaningful differentiation.
No method-of-use patent is publicly identified as a major commercial barrier for Plasmanate.
What is the Orange Book and Purple Book status of PPF?
Plasma protein fraction is a biologic and is not expected to have the standard Orange Book patent-and-exclusivity profile associated with drugs such as small-molecule anticoagulants or antibiotics.
The relevant distinctions are:
| Regulatory question |
PPF position |
| Is PPF a conventional NDA product? |
No |
| Is it generally substituted through an ANDA? |
No |
| Is an Orange Book patent listing the primary barrier? |
No |
| Is it a biologic licensed under a BLA? |
Yes |
| Could a competitor require a biologics license? |
Yes |
| Is automatic pharmacy-level substitution expected? |
No |
| Is a mature biosimilar market established? |
No |
A competing plasma-derived product would likely require a biologics license and extensive manufacturing comparability. The regulatory pathway would depend on the product’s composition, manufacturing process, reference product, clinical evidence and FDA assessment.
How strong is the PPF patent estate?
The patent estate is weak as a source of exclusivity but the manufacturing estate is difficult to replicate.
| Protection category |
Commercial strength |
| Core composition patent |
Low |
| 5% formulation protection |
Low |
| Method-of-use patents |
Low |
| Source-plasma access |
High |
| Fractionation know-how |
High |
| Viral-safety validation |
High |
| Regulatory manufacturing history |
High |
| Hospital and distributor relationships |
Moderate |
| Cold-chain and inventory infrastructure |
Moderate |
This creates a common structure for mature plasma-derived products: low formal patent protection paired with high execution barriers.
A new entrant could avoid an expired patent by using an alternative fractionation or stabilization process. It could not avoid the need to demonstrate reliable viral safety, product consistency and supply continuity.
Which companies compete with plasma protein fraction?
The main competitors are not necessarily identical PPF products. Hospitals can select other products for volume expansion, depending on clinical circumstances, formulary rules and physician preference.
Human albumin
Human albumin is the closest plasma-derived substitute. It is available in multiple concentrations, including 5% and 25%. Albumin has broader clinical use and greater commercial visibility than PPF. It is used for volume replacement, hypoalbuminemia-related conditions and selected specialty indications.
Albumin’s established supply chains and broad hospital use make it a significant competitive constraint on PPF.
Crystalloids
Normal saline, balanced electrolyte solutions and other crystalloids are lower-cost alternatives for many volume-replacement situations. Their low acquisition cost limits the use of plasma-derived products where the clinical objective can be met without a protein-based product.
Synthetic colloids
Synthetic colloids have historically competed with plasma-derived products, although safety concerns and changing clinical practice have limited their role in some markets. Their position varies by jurisdiction and hospital protocol.
Other plasma-derived products
Other plasma-derived volume expanders may compete in selected jurisdictions. Availability depends on local licensing, hospital procurement and the manufacturer’s plasma fractionation portfolio.
What drives the market for plasma protein fraction?
PPF demand is shaped by hospital utilization rather than consumer prescribing. Key drivers include:
- Trauma and acute blood-loss management;
- Surgical volume;
- Intensive-care utilization;
- Emergency department protocols;
- Blood-product availability;
- Hospital formulary decisions;
- Relative pricing versus albumin and crystalloids;
- Plasma collection volumes;
- Product shortages and allocation policies.
The market is therefore sensitive to both clinical practice and supply conditions. A reduction in invasive surgery or a shift toward crystalloid-based resuscitation can reduce demand. Conversely, blood-product shortages or disruptions in plasma-derived albumin supply can increase demand for alternative protein-volume products.
The U.S. market is likely to remain concentrated because the product is mature, hospital-based and operationally complex. It does not have the growth characteristics of a specialty biologic with expanding indications.
What is the financial trajectory of plasma protein fraction?
No major manufacturer publicly reports standalone PPF revenue. Grifols reports financial results by broader business segments and product categories rather than isolating Plasmanate sales. As a result, product-level revenue, gross margin and market share are not publicly quantifiable from company filings.
The commercial trajectory is best characterized as mature and low-growth:
| Financial factor |
Expected effect |
| Product maturity |
Limits unit and price growth |
| Hospital demand |
Creates recurring but concentrated sales |
| Albumin competition |
Restricts pricing power |
| Plasma costs |
Pressures gross margin |
| Manufacturing scale |
Supports profitability for established producers |
| Supply shortages |
Can increase short-term pricing and demand |
| Lack of patent exclusivity |
Limits premium pricing |
| Regulatory complexity |
Discourages new entrants |
| Product-level disclosure |
Prevents precise revenue modeling |
Grifols’ broader plasma-derived portfolio benefits from scale in plasma collection, fractionation and global distribution. PPF can share infrastructure with albumin and other plasma-derived products, which lowers incremental manufacturing costs for an established producer. That benefit is less accessible to a stand-alone entrant.
PPF revenue exposure is likely modest relative to Grifols’ major products, particularly albumin and immunoglobulins. The product is strategically more relevant as part of a plasma-fractionation portfolio than as a standalone growth asset.
What generic or biosimilar launch risks exist?
A conventional generic launch is unlikely to be the principal competitive scenario. The more relevant risk is entry by another manufacturer of a licensed plasma-derived product with comparable composition and clinical use.
Potential launch scenarios include:
- A competing 5% human plasma-protein product enters after securing a biologics license.
- A hospital system shifts utilization from PPF to 5% albumin.
- A distributor uses price competition to gain formulary access.
- A supply disruption creates temporary demand for alternative products.
- A manufacturer expands capacity and reduces dependence on a single supplier.
Automatic substitution would not be expected in the same way as substitution between therapeutically equivalent small-molecule generics. Hospital pharmacy committees, physician protocols and procurement contracts would influence uptake.
The largest near-term commercial risk is substitution by albumin and crystalloids rather than a patent-driven generic cliff.
What patent litigation, Paragraph IV challenges and settlements affect PPF?
No major Paragraph IV challenge, Orange Book patent litigation or public settlement agreement is identified as a defining event for plasma protein fraction. Paragraph IV litigation is primarily associated with ANDA products and listed small-molecule patents. PPF’s biologic regulatory status makes that framework less relevant.
No public litigation event is identified as materially altering the U.S. market structure for Plasmanate. The principal disputes affecting plasma-derived products tend to involve manufacturing, supply, product liability, contracts or regulatory compliance rather than patent validity and infringement.
What geographic markets matter for PPF?
The United States is the most commercially relevant market for Plasmanate because of its established FDA license and hospital distribution network. International markets depend on country-specific marketing authorizations and plasma-derived-product rules.
Geographic expansion is constrained by:
- National plasma-collection policies;
- Import and export controls;
- Local biologics licensing;
- Cold-chain requirements;
- Reimbursement rules;
- Hospital procurement systems;
- Local acceptance of plasma-derived products.
A manufacturer with global plasma infrastructure has a structural advantage because the product can be integrated into broader regional distribution and fractionation operations.
How does PPF compare with human albumin?
| Factor |
Plasma protein fraction |
Human albumin |
| Protein composition |
Mixed plasma proteins |
Predominantly albumin |
| Typical concentration |
5% |
5% and 25% widely used |
| Market maturity |
Mature niche |
Mature, broader market |
| Patent-driven protection |
Minimal |
Minimal for core product |
| Clinical breadth |
Narrower |
Broader |
| Manufacturing barrier |
High |
High |
| Public revenue visibility |
Limited |
Higher at portfolio level |
| Main competitive risk |
Albumin substitution |
Crystalloid and albumin-price pressure |
Albumin has the stronger commercial position because it has broader recognition, more indications and deeper hospital utilization. PPF retains value where its labeled use and product availability fit local clinical protocols.
Key Takeaways
- Plasma protein fraction (human) is a mature plasma-derived biologic, principally represented in the U.S. by Grifols’ Plasmanate.
- Its FDA license remains the central regulatory reference; conventional Orange Book exclusivity is not the relevant framework.
- Core patent protection is no longer the main commercial barrier.
- Source-plasma access, fractionation capacity, viral-safety validation and regulatory manufacturing history provide the strongest protection.
- Human albumin is the closest and most important commercial substitute.
- Crystalloids impose persistent price pressure in hospital volume-replacement protocols.
- No major Paragraph IV challenge, patent settlement or Orange Book litigation drives current PPF competition.
- Product-level revenue is not separately disclosed by Grifols, preventing a precise standalone financial forecast.
- The product’s financial trajectory is mature, recurring and operationally dependent rather than innovation-led.
- The most credible competitive threat is clinical and formulary substitution, not a conventional generic patent cliff.
FAQs
Is plasma protein fraction the same as albumin?
No. PPF contains a mixture of human plasma proteins, while albumin products are primarily purified human albumin. Both can be used for plasma-volume replacement, but they have different compositions, labels and clinical positioning.
Can a generic manufacturer copy Plasmanate?
A conventional ANDA generic pathway is not the expected route. A competing manufacturer would generally need to pursue a biologics license supported by validated plasma sourcing, fractionation, viral-safety and quality-control systems.
Does Plasmanate have remaining FDA exclusivity?
No meaningful original-product exclusivity remains. Its commercial position depends on manufacturing capability, supply reliability and hospital adoption.
Is plasma protein fraction listed in the Orange Book?
PPF is not generally managed through the standard Orange Book framework used for NDA and ANDA small-molecule products. Its primary regulatory record is the biologics license and FDA product labeling.
What is the largest financial risk for PPF sales?
The largest risk is substitution by human albumin or lower-cost crystalloids, combined with limited market growth and the absence of patent-based pricing power.
References
-
Grifols, S.A. (2024). Annual report 2023. Grifols.
-
U.S. Food and Drug Administration. (n.d.). Plasmanate: Plasma protein fraction, human, 5% prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Purple Book database of licensed biological products. FDA.
-
U.S. Food and Drug Administration. (2024). Development and licensure of plasma-derived products. FDA.
-
U.S. Pharmacopeial Convention. (2024). Plasma protein fraction, human: United States Pharmacopeia monograph. USP.
